Clinical Trials Using Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949

Clinical trials are research studies that involve people. The clinical trials on this list are studying Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • CMP-001 and INCAGN01949 for the Treatment of Patients with Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

    This phase Ib / II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma. CMP-001 is made up of a short piece of DNA that is packaged in a protein, known as a virus-like particle (VLP). VLPs are detected and processed by cells of the immune system. The DNA contained in CMP-001 activates the immune system and recruit cells of the immune system to the tumor. INCAGN01949 is an antibody, a type of protein, which has been shown to stimulate the immune system. Injecting CMP-001 and INCAGN01949 directly into the tumor may work against tumor cells to slow tumor growth by causing tumor cells to die.
    Location: 4 locations